Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

brontictuzumab

A humanized monoclonal antibody directed against the Notch-1 receptor with potential antineoplastic activity. Upon administration, brontictuzumab binds to Notch-1 on the cell surface, thereby inhibiting Notch-mediated signaling and tumor cell proliferation. Notch 1, a type 1 transmembrane protein belonging to the Notch family, functions as a receptor for membrane bound ligands and has various roles during development; dysregulated Notch signaling is associated with increased cell growth and chemoresistance in cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-Notch1 monoclonal antibody OMP-52M51
immunoglobulin G2-lambda, anti-(homo sapiens Notch1 (Notch 1, translocation-associated Notch-1, TAN-1,Tan1)), humanized monoclonal antibody
Code name:OMP-52M51
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search